StreetAlpha.app
Home › Stocks › TLSI

TriSalus Life Sciences, Inc. (TLSI)

$2.29
▲ +1.10%
LAST CLOSE · NOV 17

TriSalus Life Sciences makes the TriNav medical device and sells it mainly to hospitals and physicians. It last closed at $2.29 on Nov 17, up 1.10% on the day. The average 12-month price target from 2 analysts is $7.00 (+205.0% from the last close), with a high of $10.00 and a low of $4.00.

AI Auto Pilots
Is TLSI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$46.4M
+15.4% vs a year ago
Net income
−$26.3M
−56.6% margin
EPS (diluted)
−$0.41
Free cash flow
−$24.7M
−53.3% margin
Valuation
Market cap
$141.6M
61.7M shares
P/E
–
No P/E while losing money
Price to sales
3.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.1M
At Sep 30
Debt
$32.4M
At Sep 30
Shareholder equity
$680K
Shares outstanding
61.7M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $12.4M$12.4MFY2022FY2023: $18.5M$18.5MFY2023FY2024: $29.4M$29.4MFY2024FY2025: $45.2M$45.2MFY2025

From TLSI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated TLSI in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 205.0% upside

Based on 2 analysts who set a price target on TLSI in the past 90 days. The average target is $7.00, with a high of $10.00 and a low of $4.00, compared with the last close of $2.29.

Low $4.00Avg $7.00High $10.00
Blue marker: last close $2.29
Highest target$10.00
Average target$7.00
Lowest target$4.00
Latest rating changes
Canaccord GenuityMaintained
Nov 11Buy$4
HC Wainwright & Co.Target lowered
Nov 11Buy$12 → $10
HC Wainwright & Co.Target raised
Sep 23Buy$11 → $12
HC Wainwright & Co.Initiated
Sep 9Buy$11
DateFirmActionRatingPrice target
Nov 11Canaccord GenuityMaintainedBuy$4
Nov 11HC Wainwright & Co.Target loweredBuy$12 → $10
Sep 23HC Wainwright & Co.Target raisedBuy$11 → $12
Sep 9HC Wainwright & Co.InitiatedBuy$11
Loading…

Technical Analysis

TLSI · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 43% below its 20 day and 72% below its 50 day average. It is 86% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the Pivot at $2.27, and the nearest resistance the Pivot R1 at $2.36.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.6%/day
Key levels
$7.9552 week high+247.2%
$4.34100 day average+89.5%
$4.26200 day average+86.0%
$3.9450 day average+72.1%
$3.68Swing high (Jun 1)+60.7%
$3.2720 day average+42.8%
$2.36Pivot R1+3.1%
$2.29Last close
$2.27Pivot−0.9%
$2.20Pivot S1−3.9%
$2.1752 week low−5.2%
Indicators
RSI (14)26.87Oversold below 30Oversold
MACD-0.46Below its signal lineBearish
Stochastic8.0Near the bottom of its rangeOversold
ADX (14)25.9Trending down
Williams %R-93.2Oversold below −80, overbought above −20Oversold
CCI (20)-132.4Oversold below −100, overbought above 100Oversold
Rate of change−34.0%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 14.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TLSI

What happened before

See how TLSI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TLSI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TLSI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TLSI in the last 90 days.

Loading…

See today’s whale options flow across the market →

TLSI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●35 buying vs 36 selling
  • ▼Held by funds -0.9 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8279+3.8%
In funds' top 10110.0%
Held by funds36.0%36.9%−0.9 pts
New / increased11 / 2411 / 45−37.5%
Reduced / sold out30 / 610 / 15+44.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TLSI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TLSI is in one of them and how their past TLSI trades turned out.

TLSI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TLSI in an article yet. Here's the latest on the wider market.

About TriSalus Life Sciences

TriSalus Life Sciences is a medical device company based in Westminster, Colorado. It sells its TriNav device to hospitals and physicians, often through consignment agreements. The company is also developing other products that are still in preclinical studies and clinical trials. Its customers are mainly hospitals and the physicians who use its products to treat patients.

Headquarters
Westminster, CO